Markedly different rates and resistance profiles exhibited by seven commonly used and newer β-lactams on the selection of resistant variants of Enterobacter cloacae

被引:18
作者
Chan, WC
Li, RC [1 ]
Ling, JM
Cheng, AF
Schentag, JJ
机构
[1] Chinese Univ Hong Kong, Dept Pharm, Shatin, Peoples R China
[2] Chinese Univ Hong Kong, Dept Microbiol, Shatin, Peoples R China
[3] SUNY Buffalo, Sch Pharm, Dept Pharmaceut, Buffalo, NY 14260 USA
关键词
D O I
10.1093/jac/43.1.55
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Seven beta-lactam antibiotics (cefepime, cefoperazone, ceftazidime, ceftriaxone, cefamandole, imipenem and meropenem) were tested for their potential to select resistance in standard and clinical strains of Enterobacter cloacae (n = 9). The strains were subcultured daily with the test antibiotics at doubling concentrations starting at 0.125 x MIG. Development of resistance throughout the passages was detected by a disc diffusion test. Ceftazidime, ceftriaxone and cefamandole selected resistance at a faster rate than cefoperazone, cefepime and meropenem. Imipenem did not select resistance in the nine strains tested and was the only antibiotic that eradicated all the strains during selection. The resistance patterns of strains selected by meropenem, cefepime and the other cephalosporins were markedly different, although cross-resistance to the early generation cephalosporins was common. The resistance phenotypes of most strains remained stable upon serial passages in antibiotic-free medium. The findings of this study highlight the importance of the choice of antibiotic for therapy not only on the basis of its antibacterial activity, but also on its potential to select resistance to itself and other antibiotics.
引用
收藏
页码:55 / 60
页数:6
相关论文
共 17 条
[1]  
[Anonymous], 1993, M7A3 NCCLS
[2]   SELECTION FREQUENCY OF RESISTANT VARIANTS BY VARIOUS BETA-LACTAM ANTIBIOTICS IN CLINICAL ENTEROBACTER-CLOACAE ISOLATES [J].
BUSCHER, KH ;
CULLMANN, W ;
DICK, W ;
STIEGLITZ, M .
CHEMOTHERAPY, 1987, 33 (01) :40-51
[3]   ENTEROBACTER BACTEREMIA - CLINICAL-FEATURES AND EMERGENCE OF ANTIBIOTIC-RESISTANCE DURING THERAPY [J].
CHOW, JW ;
FINE, MJ ;
SHLAES, DM ;
QUINN, JP ;
HOOPER, DC ;
JOHNSON, MP ;
RAMPHAL, R ;
WAGENER, MM ;
MIYASHIRO, DK ;
YU, VL .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (08) :585-590
[4]   EPIDEMIOLOGY OF DRUG-RESISTANCE - IMPLICATIONS FOR A POSTANTIMICROBIAL ERA [J].
COHEN, ML .
SCIENCE, 1992, 257 (5073) :1050-1055
[5]   Sequencing and analysis of four new Enterobacter ampD alleles [J].
Ehrhardt, AF ;
Sanders, CC ;
Romero, JR ;
Leser, JS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1953-1956
[6]   Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins [J].
FungTomc, JC ;
Gradelski, E ;
Huczko, E ;
Dougherty, TJ ;
Kessler, RE ;
Bonner, DP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (05) :1289-1293
[7]   ENTEROBACTER - AN EMERGING NOSOCOMIAL PATHOGEN [J].
GASTON, MA .
JOURNAL OF HOSPITAL INFECTION, 1988, 11 (03) :197-208
[8]   TRENDS IN METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS IN UNITED-STATES HOSPITALS [J].
GAYNES, RP ;
CULVER, DH ;
HORAN, TC ;
HENDERSON, TS ;
TOLSON, JS ;
MARTONE, WJ .
INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1993, 2 (06) :452-455
[9]  
MCGOWAN JE, 1983, REV INFECT DIS, V5, P1033
[10]   HOW PREDICTABLE IS DEVELOPMENT OF RESISTANCE AFTER BETA-LACTAM THERAPY IN ENTEROBACTER-CLOACAE INFECTION [J].
MICHEAHAMZEHPOUR, M ;
PECHERE, JC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 24 (03) :387-395